Peer-reviewedCC BY-NC-NDInternal Medicine
TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351
Abstract
A 49-year-old man developed therapy-related acute myeloid leukemia (t-AML) nine years after undergoing treatment for acute promyelocytic leukemia. A genetic analysis revealed a TP53 mutation and a complex karyotype featuring der(5;17)(p10;q10) translocation. This combination is associated with an extremely poor prognosis and chemoresistance. However, the patient achieved complete remission with CPX-351 (liposomal daunorubicin/cytarabine) and subsequently underwent allogeneic hematopoietic stem cell transplantation. He has remained in remission for over five months after the transplant. CPX-351 followed by early transplantation may be an important therapeutic option for selected high-risk patients, such as those with TP53-mutatied t-AML.
Related
- BLINATUMOMAB AS A BRIDGE THERAPY TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY TO MULTIPLE CHEMOTHERAPY REGIMENS: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE NEGATIVITY AND IMPACT ON OUTCOME
- High sperm DNA fragmentation is associated with increased embryonic chromosomal abnormality: a retrospective study of 8 years involving 5637 couples undergoing ART.
- Immune-Mediated Demyelinating Central Nervous System Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- A randomized controlled trial of a multidisciplinary collaborative fatigue management program for patients undergoing hematopoietic stem cell transplantation: study protocol
BibTeX
@article{kamiya2026tp53mutated,
title = {{TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351}},
author = {Aya Kamiya and Yoshinori Hashimoto and Hiromi Omura and Takayuki Tanaka},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.7870-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7870-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351
AU - Aya Kamiya
AU - Yoshinori Hashimoto
AU - Hiromi Omura
AU - Takayuki Tanaka
PY - 2026
DA - 2026/08/08
JO - Internal Medicine
DO - 10.2169/internalmedicine.7870-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7870-26/_article
AB - A 49-year-old man developed therapy-related acute myeloid leukemia (t-AML) nine years after undergoing treatment for acute promyelocytic leukemia. A genetic analysis revealed a TP53 mutation and a complex karyotype featuring der(5;17)(p10;q10) translocation. This combination is associated with an extremely poor prognosis and chemoresistance. However, the patient achieved complete remission with CPX-351 (liposomal daunorubicin/cytarabine) and subsequently underwent allogeneic hematopoietic stem cell transplantation. He has remained in remission for over five months after the transplant. CPX-351 followed by early transplantation may be an important therapeutic option for selected high-risk patients, such as those with TP53-mutatied t-AML.
SN - 1349-7235
SN - 0918-2918
ER -